Trial Profile
Specific Use Result Survey of PRALIA 60 mg Subcutaneous Injection Syringe - A Long-term Use Survey in Patients with Rheumatoid Arthritis -
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.
- 31 Oct 2017 New trial record